Results 1 to 4 of 4

Thread: Egrifta???

  1. #1
    LouisFit16 is offline Junior Member
    Join Date
    Jan 2008


    Has anyone heard of this stuff before... a friend of mine told me about it... i never heard of it before... any feed back or anything would be helpful... thanks

  2. #2
    Hazard's Avatar
    Hazard is offline AR-Elite Hall of Famer
    Join Date
    Mar 2004
    It's a growth hormone releasing agent..... - US prescription only

    Failure is not and option..... ONLY beyond failure is - Haz

    Think beyond yourselves and remember this forum is for educated members to help advise SAFE usage of AAS, not just tell you what you want to hear
    - Knockout_Power


  3. #3
    Hazard's Avatar
    Hazard is offline AR-Elite Hall of Famer
    Join Date
    Mar 2004
    Taken from:
    FDA Approves Egrifta

    The U.S. Food and Drug Administration (FDA) has approved Egrifta (tesamorelin for injection), a synthetic analogue of growth hormone releasing factor, as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy).

    Egrifta Patient Information

    Read the patient information that comes with Egrifta before you start to take it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment.
    What is Egrifta?

    • <LI itxtHarvested="1" itxtNodeId="111">Egrifta is an injectable prescription medicine to reduce the excess in abdominal fat in HIV-infected patients with lipodystrophy. Egrifta contains a growth hormone-releasing factor (GRF). <LI itxtHarvested="1" itxtNodeId="110">the impact and safety of Egrifta on cardiovascular health has not been studied. <LI itxtHarvested="1" itxtNodeId="109">Egrifta is not indicated for weightloss management. <LI itxtHarvested="1" itxtNodeId="108">it is not known whether taking Egrifta helps improve compliance with anti-retroviral medications.
    • it is not known if Egrifta is safe and effective in children. Egrifta is not recommended to be used in children.
    Who should not use Egrifta?

    Do not use Egrifta if you:
    • <LI itxtHarvested="1" itxtNodeId="143">have pituitary gland tumor, pituitary gland surgery or other problems related to your pituitary gland. <LI itxtHarvested="1" itxtNodeId="142">have or had a history of active cancer (either newly diagnosed or recurrent). <LI itxtHarvested="1" itxtNodeId="141">are allergic to tesamorelin of any of the ingredients listed in Egrifta. See the end of this leaflet for a complete list of ingredients in Egrifta.
    • are pregnant or becomepregnant. If you become pregnant, stop using Egrifta and talk to your healthcare provider. See "What should I tell my healthcare provider before using Egrifta?"
    What should I tell my healthcare provider before using Egrifta?

    Before using Egrifta, tell you healthcare provider if you:
    • <LI itxtHarvested="1" itxtNodeId="148">have or have had cancer <LI itxtHarvested="1" itxtNodeId="147">have diabetes <LI itxtHarvested="1" itxtNodeId="146">are breastfeeding or plan to breastfeed. It is not known if Egrifta passes into your breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers do not breastfeed to avoid the risk of passing HIV infection to your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking Egrifta. <LI itxtHarvested="1" itxtNodeId="145">have kidney or liver problems
    • have any other medical condition.
    Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Egrifta may affect the way other medicines work, and other medicines may affect how Egrifta works.
    Know the medicines you take. Keep a list with you to show your healthcare provider and pharmacist when you get a new medicine.
    How should I use Egrifta?

    • <LI itxtHarvested="1" itxtNodeId="153">Read the detailed "Instructions for Use" that comes with Egrifta before you start using Egrifta. You healthcare provider with show you how to inject Egrifta. <LI itxtHarvested="1" itxtNodeId="152">Use Egrifta exactly as prescribed by your healthcare provider. <LI itxtHarvested="1" itxtNodeId="151">Inject Egrifta under the skin (subcutaneously) of your stomach area (abdomen). <LI itxtHarvested="1" itxtNodeId="150">Change (rotate) the injection site on your stomach area (abdomen) with each dose. Do not inject Egrifta into scar tissue, bruises or your navel.
    • Do not share needles or syringes with other people. Sharing of needles can result in the transmission of infectious diseases, such as HIV.
    Egrifta side effects

    Egrifta may cause serious side effects including:
    • <LI itxtHarvested="1" itxtNodeId="185">Serious allergic reaction. Some people taking Egrifta may have an allergic reaction.
      Stop using Egrifta and get emergency help right away if you have any of the following symptoms:
      • <LI itxtHarvested="1" itxtNodeId="194">a rash over your body <LI itxtHarvested="1" itxtNodeId="193">hives <LI itxtHarvested="1" itxtNodeId="192">swelling of your face or throat <LI itxtHarvested="1" itxtNodeId="191">shortness of breath or troublebreathing <LI itxtHarvested="1" itxtNodeId="190">fast heartbeat
      • feeling of faintness or fainting
      <LI itxtHarvested="1" itxtNodeId="184">Swelling (fluid retention). Egrifta can cause swelling in some parts of your body. Call your healthcare provider if you have an increase in joint pain, or pain or numbness in your hands or wrist (carpal tunnel syndrome). <LI itxtHarvested="1" itxtNodeId="183">Increase in glucose (blood sugar) intolerance and diabetes. Your healthcare provider will measure your blood sugar periodically. <LI itxtHarvested="1" itxtNodeId="182">Injection site reactions. Change (rotate) your injection site to help lower your risk for injection site reactions. Call your healthcare provider for medical advice if you have the following symptoms around the area of the injection site:
      • <LI itxtHarvested="1" itxtNodeId="205">redness <LI itxtHarvested="1" itxtNodeId="204">itching <LI itxtHarvested="1" itxtNodeId="203">pain <LI itxtHarvested="1" itxtNodeId="202">irritation <LI itxtHarvested="1" itxtNodeId="201">bleeding
      • rash
      • swelling
    The most common side effects of Egrifta include:
    • <LI itxtHarvested="1" itxtNodeId="214">joint pain <LI itxtHarvested="1" itxtNodeId="213">pain in legs and arms <LI itxtHarvested="1" itxtNodeId="212">swelling in your legs <LI itxtHarvested="1" itxtNodeId="211">muscle soreness <LI itxtHarvested="1" itxtNodeId="210">tingling, numbness and prickling <LI itxtHarvested="1" itxtNodeId="209">nausea <LI itxtHarvested="1" itxtNodeId="208">vomiting <LI itxtHarvested="1" itxtNodeId="207">rash
    • itching
    Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
    These are not all the possible side effects of Egrifta. For more information, ask you healthcare provider or pharmacist.
    Call you doctor for medical advice about side effects. To report side effects, contact EMD Serono toll-free at 1-800-283-8088 ext. 5563. You may report side effects to FDA at 1-800-FDA-1088.
    See also: Egrifta side effects (in more detail)
    How do I store Egrifta?

    • <LI itxtHarvested="1" itxtNodeId="221">Egrifta has two boxes
      • <LI itxtHarvested="1" itxtNodeId="224">Store the Medication Box of Egrifta vials in the refrigerator between 2C and 8C (36F and 46F).
      • Store the box of Sterile Water for Injection, syringes and needles at room temperature between 20C to 25C (68F to 77F).
      <LI itxtHarvested="1" itxtNodeId="220">Keep Egrifta vials in Medication Box away from light. <LI itxtHarvested="1" itxtNodeId="219">Do not freeze. <LI itxtHarvested="1" itxtNodeId="218">Do not use Egrifta after the expiration date printed on the carton and vial labels.
    • After mixing, use Egrifta right away and throw away any unused Egrifta. Do not store mixed Egrifta. Also, throw away the used vial of Sterile Water for Injection
    Keep Egrifta and all medicines out of the reach of children.
    General information about the safe and effective use of Egrifta

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Egrifta for a condition for which it was not prescribed. Do not give Egrifta to other people, even if they have the same symptoms you have. It may harm them.
    Do not share your Egrifta syringe with another person, even if the needle is changed. Do not share your Egrifta needles with another person.
    This Patient Information leaflet summarizes the most important information about Egrifta. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Egrifta that is written for healthcare professionals.
    For more information about Egrifta, go to or contact AXIS Center toll-free at 1-877-714-2947.
    What are the ingredients in Egrifta?

    Active ingredient: tesamorelin
    Inactive ingredients: mannitol and Sterile Water for Injection

    Failure is not and option..... ONLY beyond failure is - Haz

    Think beyond yourselves and remember this forum is for educated members to help advise SAFE usage of AAS, not just tell you what you want to hear
    - Knockout_Power


  4. #4
    Mpldja is offline New Member
    Join Date
    Jul 2011
    Just started it today. So far no adverse reactions. Still hoping for a faster results rate. Any experienced input would be greatly appreciated.

Thread Information

Users Browsing this Thread

There are currently 1 users browsing this thread. (0 members and 1 guests)

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts